DSC Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

DSC Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-37,500	Closed	-$852K	–	76
2016 Q3	$852K	Hold	37,500	–	–	0.52%	28
2016 Q2	$885K	Hold	37,500	–	–	0.56%	33
2016 Q1	$765K	Buy	37,500 +12,500	+50%	+$397K	0.45%	35
2015 Q4	$1.29M	Hold	25,000	–	–	0.67%	27
2015 Q3	$1.07M	Hold	25,000	–	–	0.52%	44
2015 Q2	$1.14M	Hold	25,000	–	–	0.59%	34
2015 Q1	$949K	Buy	+25,000	New	+$859K	0.5%	37

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DSC Advisors's PTLA Position: Q4 2016 in Review

DSC Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2016, closing a stake of 37,500 shares — an estimated $852K sold.

DSC Advisors first reported a position in PTLA in Q1 2015 and held it in 7 quarters. The position peaked at $1.29M in Q4 2015. 150 funds tracked by Wall St. Rank hold PTLA as of Q4 2016.

DSC Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
DSC Advisors sold 37,500 Portola Pharmaceuticals, Inc. shares in Q4 2016, an estimated $852K.
DSC Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 7 quarters.
DSC Advisors's Portola Pharmaceuticals, Inc. position peaked at $1.29M in Q4 2015.
150 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2016.

Based on DSC Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.